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Abstract
Introduction: There is an ever-increasing need for animal models to evaluate efficacy and safety of new
therapeutics in the field of rheumatoid arthritis (RA). Particularly for the early preclinical evaluation of human-
specific biologicals targeting the progressive phase of the disease, there is a need for relevant animal models. In
response to this requirement we set out to develop a model of collagen-induced arthritis (CIA) in a small-sized
nonhuman primate species (300 to 400 g at adult age); that is, the common marmoset (Callithrix jacchus).
Methods: Twenty-two animals divided into three experiments were immunized with collagen type II (CII) of either
bovine or chicken origin with different immunization strategies. The animals were analyzed for clinical
manifestation of arthritis, hematology and clinical chemistry, immunological responses against CII and
histopathological features of the arthritis.
Results: Clinically manifest arthritis was observed in almost 100% (21 out of 22) of the animals. Fifty percent of the
animals developed semi-acute CIA while the other 50% displayed a more chronic disease. Both cellular (CD3/CD4
and CD3/CD8) and humoral responses (IgM and IgG) against CII were involved in the development of the disease.
Besides mild histopathological changes in bone and cartilage, severe inflammation in extraarticular tissues like
periosteum and subcutaneous tissues was observed.
Conclusions: This new model in marmosets more closely resembles chronic RA with respect to the chronic
disease course and pathomorphological presentation than the more acute monophasic and destructive CIA model
in macaques. This model can therefore fill a niche in preclinical testing of new human specific therapeutics.
Introduction
The drug development industry continues to invest
heavily in the development of new drugs against rheu-
matoid arthritis (RA) based on biological regulators and
antagonists of proinflammatory molecules, such as
monoclonal antibodies or soluble receptor molecules.
The investments are based on the expectation that bio-
logical drugs will act more specifically and with less side
effects than the classical broad-acting nonbiological dis-
ease-modifying and anti-inflammatory treatments. Biolo-
gical molecules have their own safety problems that are
not experienced with non-biological molecules, however,
such as induction of neutralizing immunity or
hypersensitivity reactions caused by massive cytokine
release or activation of the complement system. Owing
to the high species and target molecule specificity, biolo-
gical drugs are often not active in lower animal models,
such as mice and rats. This implies for a considerable
proportion of the new biological therapeutics that the
classical disease models are not a feasible option for pre-
clinical safety and efficacy assessment, leaving nonhu-
man primates as the only relevant species [1].
The rhesus and cynomolgus macaque models of col-
lagen-induced arthritis (CIA) provide useful disease
models that have allowed for the efficacy evaluation of
new therapeutics [2-4]. These models, however, also
have a number of disadvantages. First, macaques are
large-sized animals ( > 6 kg at adult age) requiring sub-
stantial quantities of test substance to achieve an effec-
tive dose. Second, the outbred nature of the model is
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translated into considerable clinicopathological hetero-
geneity between individual monkeys. As we strive to
perform experiments with treatment groups comprising
a small number of animals (usually five to seven ani-
mals), beneficial effects of less robust therapeutics are
often overlooked. Third, the disease in macaques is
often severe, short lasting and self-limiting, which limits
the operational window of therapies that are adminis-
tered after clinical manifestation of the arthritis.
Similar disadvantages in macaque models of another
experimental autoimmune-inflammatory disorder mod-
eled on multiple sclerosis - that is, experimental autoim-
mune encephalomyelitis (EAE) - have triggered the
search for an alternative model that does not have these
disadvantages. As reviewed elsewhere, the EAE model in
common marmosets (Callithrix jacchus) provides a use-
ful and often superior alternative [5-7]. The common
marmoset is a small-sized Neotropical primate (±350 g
at adult age) born as non-identical twins or triplets with
chimeric bone marrows due to fusion of the placental
bloodstreams [8]. Immune cells of the hemopoietic sys-
tems of fraternal twins distribute equally over each sib-
ling, and cells of the T-lymphocyte and B-lymphocyte
lineage are educated in the same thymic compartments.
This implies that the immune systems of twins are
highly comparable [9], creating the unique situation that
the twin sibling can be used as the optimal control for
each monkey in an experimental group. Probably the
most important feature of the model is that, in the clini-
cal and pathological presentation, EAE in marmosets
more closely resembles multiple sclerosis, whereas the
corresponding models in rhesus monkeys rather resem-
ble acute neuroinflammatory diseases, such as acute dis-
seminated encephalomyelitis [10,11].
The aim of the current study was to investigate
whether the advantages of the marmoset as a model for
EAE could be transferred to the CIA model. We report
here that almost 100% of marmosets sensitized against
commercial bovine or chicken-type collagen develop
clinically manifest arthritis. About 50% of animals
develop a long-lasting disease with a mainly relapsing/
remitting course. In the remaining 50% of animals, a
more short-lasting disease course was observed. Patho-
morphological changes in arthritic joints were consistent
with moderate to marked inflammation of the synovium,
fibrous capsule, periosteum and subcutis, accompanied
by moderate edema, reactive synoviocytes and reactive
blood vessels. Loss of chondrocytes and collagen disrup-
tion and small foci of bone resorption were present. In
addition, several biomarkers were evaluated that have
been developed for the CIA model in the rhesus mon-
key [3,4,12,13] proved to be valid also in marmosets.
Materials and methods
Animals
Healthy male and female marmosets of adult age ( > 1.5
years) were supplied by the Institute’s Animal Science
Department. Individual data of the animals are pre-
sented in Table 1. Before inclusion into an experiment,
each monkey received a complete health check by the
veterinary staff, including assessment hematological, ser-
ological and microbiological abnormalities. During the
experiments the monkeys were housed in pairs in spa-
cious cages with cage enrichment and padded shelter
provided. The daily diet during the study consisted of
commercial food pellets for New World monkeys (Spe-
cial Diet Services, Essex, UK) supplemented with rice,
raisins, peanuts, marshmallows, biscuits, fresh fruit,
grasshoppers, and maggots. Drinking water ad libitum,
slurry enriched with vitamin D, and vegetables of the
season were provided.
Ethics
In accordance with the Dutch law on animal experimen-
tation, all study protocols and experimental procedures
were reviewed and approved by the Institute’s Ethics
Committee before the experiments started.
Table 1 Individual data of the monkeys
Experiment Animal Gender Age
(years)
Origin of
CIIa
Starting
weight (g)
I Mi119 Female 6.4 bo 344
Mi121 Female 5.8 bo 384
Mi125 Female 6.3 bo 364
Mi137 Female 5.6 bo 392
II M03136 Female 3.3 ch 325
M03137 Female 3.3 bo 373
M04031 Male 2.9 ch 283
M04111 Male 2.3 ch 313
M04121 Male 2.3 ch 299
M05003 Female 2.0 bo 288
M05026 Male 1.8 bo 344
M05031 Male 1.8 ch 276
M05032 Male 1.8 bo 316
M05038 Male 1.8 bo 284
M05041 Female 1.8 ch 353
M05042 Male 1.8 bo 293
III Mi012959 Male 3.4 ch 407
Mi013005 Female 3.3 ch 326
Mi013171 Male 2.9 ch 344
Mi013385 Female 2.2 ch 362
M06048 Female 1.8 ch 367
M06075 Female 1.8 ch 290
aCollagen type II (CII) purified from bovine cartilage of the knee (bo) or of
chicken origin (ch).
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Induction of collagen-induced arthritis
For the pilot study (Experiment I) a semi-purified batch
collagen type II (CII) was prepared, extracted from
bovine hyaline cartilage. For Experiments II and III, two
industry-grade commercially available types of CII were
used, respectively of bovine (bo-CII) or chicken (ch-CII)
origin (MD Biosciences, Zürich, Switzerland). Collagen
was dissolved in 0.1 M acetic acid to a final concentra-
tion of 5 mg/ml and mixed with an equal volume of
complete Freund’s adjuvant (CFA) (DIFCO, Detroit, MI,
USA). A stable emulsion was prepared by gentle stirring
of the protein/CFA emulsion for 60 minutes at room
temperature. CIA was induced by injection of 0.4 ml
emulsion into the dorsal skin distributed over four spots
of 100 μl. The final amount of CII the animals received
was 1 mg/animal. When no clinical signs of arthritis
were visible at day 28, the animals were boosted with
CII in incomplete Freund’s adjuvant (IFA) at day 35
(Experiment II)/day 28 (Experiment III) subcutaneously
in the flank.
Clinical scoring and biomarker analysis
The presence of clinical signs was recorded by daily
cage-side monitoring of behavioral changes (apathy, loss
of appetite) or pain (avoidance of limb usage). Twice
per week all monkeys were sedated by intramuscular
injection of 0.1 ml/kg ketamine (10 mg/ml) for determi-
nation of bodyweight - an accepted surrogate disease
marker for the CIA model - determination of body tem-
perature, blood collection and inspection of the limbs
for redness and/or swelling of the joints. Observations
were recorded using the discomfort management sche-
dule (Table 2).
Hematology and clinical chemistry
All hematological and clinical chemistry analyses were
performed at the Biomedical Primate Research Centre
on a Sysmex Sf-3000 (Goffin Meyvis, Etten-Leur, The
Netherlands) and a COBAS INTEGRA-400+ (Roche,
Almere, The Netherlands), respectively.
Urinalysis
Urinary excretion of the collagen crosslinks hydroxyly-
sylpyrridinoline (HP) and lysylpyrridinoline (LP) were
determined twice weekly, starting from the day of CIA
induction. For that purpose, each animal’s urine was
collected overnight in a metabolic cage. After centrifuga-
tion, the clear supernatant was isolated and stored at
-20°C. Reverse-phase high-performance liquid chromato-
graphy was used to determine HP and LP levels in
hydrolyzed urine samples as described previously [14].
The levels of HP and LP were normalized to creatinine
levels (nmol levels/mmol creatinine) to compensate for
a possible dilution by spilled drinking water.
Immunoassays
Detection of anti-collagen type II antibodies (Experiments I
and II)
Serum levels of antibodies directed against bo-CII and
ch-CII of IgM and IgG isotypes were detected by ELISA
[15]. Serum samples (0.2 ml) were collected twice
a week. Plates (96-well, F-form, microlon; Greiner
Table 2 Integrated Discomfort Score
Disease score Characteristics Monitoring Maximal durationa
0 Asymptomatic Daily End of experiment
No general discomfort signs
0.5 Fever ( > 0.5°C) Twice per week 12 weeks
1 Apathy Daily 10 weeks
Less mobility but no pain Daily
Loss of appetite Daily
2 Weight loss Twice per week 6 weeks
Warm extremities Twice per week
Treatable pain without STS Daily
3 Moderate redness + STS of joints Twice per week 4 weeks
Normal flexibility of extremities Twice per week
4 Severe redness + STS of joints Twice per week 2 weeks
With joint stiffness
5 Serious lethargy Daily 18 hours
Serious untreatable pain Daily 18 hours
Serious immobility of joints Twice per week 18 hoursb
Body weight loss >25% Twice per week 18 hoursb
STS, soft tissue swelling. aThe discomfort time combination is used in a cumulative fashion. bCan only be assessed in the sedated monkey, which cannot be done
more than twice per week for ethical reasons.
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bio-one, Alphen aan den Rijn, Netherlands) were coated
overnight at 4°C with 100 μl of a 10 μg/ml solution of
bo-CII/PBS. Plates were washed four times with PBS +
0.05 Tween-20 and subsequently blocked by a 1-hour
incubation with 200 μl PBS + 1% BSA at 37°C and 5%
CO2. Plates were washed four times, after which 100 μl
diluted serum was added (CII-IgG => 1:25; IgM =>
1:25) in PBS + 1% BSA and incubated overnight at 4°C.
After an additional incubation for 2 hours at 37°C, 5%
CO2 in a humidified atmosphere, plates were washed
four times with PBS + 0.05 Tween-20.
Plates were subsequently incubated for 1 hour with a
secondary detector antibody (AP-conjugated goat anti-
human IgM1, 10,000 in PBS + 1% BSA or AP-conju-
gated goat anti-human IgG1, 10,000 in PBS + 1% BSA;
Biosource, Camarillo, CA, USA). After washing, anti-
body binding was detected by adding 100 μl poly-nitro-
phenylphosphate diluted in Tris buffer (Sigma
Chemicals, Zwijndrecht, The Netherlands). Color devel-
opment was determined by absorbance at 405 nm.
Flow cytometry and carboxyfluorescein succinimidyl ester
staining (Experiment II)
To determine the phenotype of proliferating cells, 4 ×
106 viable peripheral blood mononuclear cells (PBMC),
axillar lymph node mononuclear cells, inguinal lymph
node mononuclear cells and spleen mononuclear cells
were suspended in 1 ml PBS and incubated for 7 min-
utes at room temperature with carboxyfluorescein succi-
nimidyl ester (final concentration, 1.5 μM; Fluka, Buchs,
Switzerland). The labeled cells were cultured for 7 days
with antigens under the standard culture conditions
described above. For flow cytometric analysis we used
the following commercially available labeled mAbs
directed against human CD markers: anti-CD3 with
PerCP or Alexa Fluor 700 label (BD Biosciences, San
Jose, CA, USA), allophycocyanin-labeled anti-CD4
(DakoCytomation, Glostrup, Denmark) and biotinylated
anti-CD8 (Serotec, Düsseldorf, Germany). Flow cyto-
metric analysis was performed on a FACSort flow cyt-
ometer using FACSDiva software (BD Biosciences).
First, viable cells were gated using the live/dead fixable
violet viability stain (Invitrogen Life Technologies,
Breda, The Netherlands). Within the viable cell gate,
lymphocytes/monocytes were selected using forward and
sideward scatter. Within the lymphocyte/monocyte gate,
CD3+ cells were selected. The CD3+ population in the
carboxyfluorescein succinimidyl ester experiment con-
sisted of CD4+ and CD8+ cells.
Ex vivo analysis of proliferative responses (Experiment III)
The maximum blood sample that can be collected in 1
month from primates at the Biomedical Primate
Research Centre should not exceed 1% of the body
weight. For an average adult common marmoset weigh-
ing 350 g, this equals a maximum monthly blood sample
of 3.5 ml. Hence, volumes of up to 1 ml at 4-week inter-
vals were collected into heparinized Vacutainer tubes
(Greiner bio-one). To measure the development of ch-
CII-specific cellular responses with time, PBMC were
isolated from heparinized venous blood using lympho-
cyte separation medium (ICN Biomedical, Aurora, OH,
USA).
In addition, cell suspensions were prepared at
necropsy from aseptically removed axillar lymph nodes,
inguinal lymph nodes and spleen. PBMC, lymph node
cells and spleen cells were cultured in RPMI medium
(HEPES-buffered) supplemented with 10% FCS, 2 mM
L-glutamax, 100 U/ml penicillin, 100 μg/ml streptomy-
cin and 2 × 10-5 M 2-Mercaptoethanol (all obtained
from Life Technologies) at 37°C in humidified air con-
taining 5% CO2. Cultures were tested in triplicate for
the detection of proliferative responses towards ch-CII
and an overlapping peptide set derived from the immu-
nogenic cyanogen bromide fragment 11 (CB11) frag-
ment (Table 3; CIIaa 124 to 402). All peptides were
dissolved in PBS and tested at a final concentration of 5
μM. ch-CII was dissolved in 0.1 M acetic acid (5 mg/
ml), denatured at 42°C for 30 minutes and tested at a
final concentration of 10 μg/ml. The proliferative
Table 3 Overlapping peptide set derived from chicken-
origin collagen type II fragment number 11 after
cyanobromide digestion
Name Amino acid numbersa Amino acid sequence
1234567890123456789012345
pep 1 124 to 149 GPRGLPGERGRPGPSGAAGARGNDG
pep 2 140 to 165 GAAGARGNDGLPGPAGPPGPVGPAG
pep 3 155 to 180 GPPGPVGPAGAPGFPGAPGSKGEAG
pep 4 170 to 195 GAPGSKGEAGPTGARGPEGAQGPRG
pep 5 185 to 210 GPEGAQGPRGESGTPGSPGPAGAPG
pep 6 200 to 225 GSPGPAGAPGNPGTDGIPGAKGSAG
pep 7 215 to 240 GIPGAKGSAGAPGIAGAPGFPGPRG
pep 8 230 to 255 GAPGFPGPRGPPGPQGATGPLGPKG
pep 9 245 to 270 GATGPLGPKGQTGEPGIAGFKGEQG
pep 10a 251 to 276 GPKGQTGEPGIAGFKGEQGPKGETG
pep 11 260 to 285 GIAGFKGEQGPKGETGPAGPQGAPG
pep 12 275 to 300 GPAGPQGAPGPAGEEGKRGARGEPG
pep 13 290 to 315 GKRGARGEPGAAGPVGPPGERGAPG
pep 14 305 to 330 GPPGERGAPGNRGFPGQDGLAGPKG
pep 15 320 to 345 GQDGLAGPKGAPGERGPAGLAGPKG
pep 16 335 to 360 GPAGLAGPKGATGDPGRPGEPGLPG
pep 17 350 to 375 GRPGEPGLPGARGLTGRPGDAGPQG
pep 18 365 to 380 GRPGDAGPQGKVGPTGAPGEDGRPG
pep 19 370 to 395 GAPGEDGRPGPPGPQGARGQPGVMG
pep 20 374 to 400 EDGRPGPPGPQGARGQPGVMGFPGP
Overlapping peptide set derived from chicken-origin collagen type II (ch-CII)
fragment number 11 after cyanobromide digestion and separation on high-
performance liquid chromatography (CB11; ch-CIIaa 124 to 402).
ach-CII amino
acid 124 = aa1.
bThis peptide contains the immunodominant glycopeptide [29].
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response was measured as [3H]thymidine incorporation.
After 72 hours of culture, 0.5 μCi [3H]thymidine was
added per well, and incorporation of the radiolabel was
determined after 18 hours using a matrix 9600 beta
counter (Packard, Meridan, CT, USA). Results of ch-
CII-specific proliferation are expressed as the mean sti-
mulation index relative to the medium control:
Stimulation index cpm experimental sample cpm medium contr= / ol.
where cpm is counts per minute. SI >2.0 was consid-
ered relevant.
Results
Incidence of collagen-induced arthritis
Three independent experiments have been performed,
involving a total of 22 marmosets. In the first experi-
ment, four marmosets were immunized according to the
standard protocol that was developed for CIA induction
in genetically susceptible rhesus monkeys; that is, a sin-
gle immunization with semi-purified bo-CII in CFA
[14,16]. All four monkeys displayed signs of CIA; that is,
painful joints, expressed by relief of pressure from the
hind legs and reluctance to manually take an offered
reward (marshmallow), and a marked loss of body
weight (Figure 1a). Sustained clinical arthritis, however,
was observed in only two monkeys (Mi121 with 10
affected joints at day 29, and Mi125 with >20 affected
joints at necropsy; Figure 1a). The two remaining ani-
mals displayed minimal clinical signs of arthritis transi-
ently and received a subcutaneous booster
immunization with bo-CII in IFA at day 114. This did
not aggravate joint swelling but did boost the induction
CII-specific IgM and IgG in Mi137. Figure 1b shows the
prominent joint swelling in the extremities of the most
severe arthritic case, Mi125. The X-ray scans depicted
in the same figure, however, do not show prominent
bone deformations in the affected hands. Histologically,
varying degrees of synovitis were observed in the joints
of two out of the four monkeys (except Mi121 - which
was found dead in the cage on day 30 - and Mi137).
Mi125 showed prominent signs of synovitis (Figure 1c).
Furthermore, histologically Mi119 displayed signs of
synovitis in clinically nonaffected joints. Erosion of the
cartilage surface was observed to start to develop in
both Mi125 and Mi119. It was concluded from this
experiment that the CIA induction protocol developed
for the rhesus monkey was suboptimal for the marmo-
set, probably because marmosets were less susceptible
to the disease.
In a second experiment, industry-grade commercial
batches of CII preparations of bovine and chicken origin
were tested. The immunization protocol comprised
inoculation with CII in CFA (intracutaneously) followed
by booster immunization with CII in IFA (subcuta-
neously). From each immunization group of six animals,
three animals were sacrificed at the peak of the disease
for histopathological examination just after the onset of
clinical disease. The remaining three animals per immu-
nization group were allowed to develop full clinical
arthritis. The animals were selected alternately to be
sacrificed early or late in the disease course. Clinical
signs of CIA were observed in all 12 cases (Integrated
Discomfort Score ≥3), but no major differences between
both collagen batches were observed (Figure 2a). A
relapsing/remitting disease course with only moderate
weight loss was observed in several cases, whereas in
other monkeys a rather acute progressive course with
serious weight loss was observed. This same clinical het-
erogeneity is observed in marmoset models of EAE [17].
This is probably a reflection of the genetically deter-
mined responsiveness to the collagen immunization, as
can be seen in the twin pairs depicted in the top of Fig-
ure 2a.
To establish reproducibility of the induction protocol,
ch-CII was selected for the third experiment (n = 6) -
the most commonly used autoantigen for CIA induction
in rodents. The images in Figure 2b confirm the high
incidence of CIA in this species (five out of six animals),
as well as the variable disease course. The one case in
which clinical signs were not observed during the 100-
day observation period did display weight loss, sugges-
tive of subclinical disease.
In conclusion, sensitization of marmosets against CII
by a first immunization with collagen in CFA followed
by booster immunizations with collagen in IFA reprodu-
cibly induces clinical arthritis in marmoset monkeys.
Clinical and pathological presentation
The alternation of overt arthritis with episodes of com-
plete remission that was observed in several cases could
also be observed at the level of a single joint. As an
example, data from M05003, which was immunized
with bo-CII in Experiment II, are shown in Figure 3.
Swollen joints at a given time point are indicated with
red circles, while the arrows indicate joints that were
found only transiently affected. The pictures at the bot-
tom of Figure 3 show the severe swelling of interphalan-
geal joints and the severe deformation of the extremities
at the end stage of the observation period.
Histological features of a representative animal with
early onset arthritis (M03136) induced with ch-CII are
depicted in Figure 4. A cross-section of a severely swol-
len joint (Figure 4a) was stained with H & E (Figure 4b).
Figure 4c shows marked extraarticular inflammation
(synovium and fibrous capsule) and loss of chondrocytes
and collagen disruption. Figure 4d zooms in on an area
where marked bone resorption takes place. Figure 4e
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shows the severe extraarticular inflammation of the peri-
osteum and subcutis. Interestingly animals that showed
marked inflammation at either the periosteum or the
subcutis were mainly found in the early responders to
induction (6/12 animals), which were also associated
with a marked loss of body weight. Inversely, animals
that showed a more chronic development of the disease
(5/12 animals) displayed no such extraarticular
phenomena.
Disease biomarkers
Inflammation
C-reactive protein is a useful serum marker of the acute
phase reaction in the rhesus monkey model of CIA.
This marker could not be detected, however, as the
detection reagents did not cross-react with C-reactive
protein of marmosets. Hematological markers such as
neutrophils and platelets were therefore analyzed on a
weekly basis. Both populations remained constant dur-
ing the observation period. Inflammation-induced ane-
mia was observed, resulting in reduced hemoglobin and
iron and reduced hematocrit values (Figure 5). The anti-
inflammatory protein albumin shows a marked
reduction in the acute responders while the late respon-
ders show a limited reduction, which recovers later on.
Joint erosion
In the rhesus monkey model of CIA, the urinary excre-
tion rate of the major collagen crosslinks LP and HP
was identified as a valid biomarker of joint erosion.
In Experiment I, a full 24-hour urinary collection was
performed to measure HP and LP excretion. Animals
that did not develop overt signs of arthritis (Mi119,
Mi137) displayed stable HP excretion, while the one ani-
mal affected by joint swelling (Mi125) showed a marked
increase in HP and LP excretion (Figure 6a, b).
In Experiment II, the time for which the animals
stayed in the metabolic cage was reduced to 16 or 17
hours to limit the discomfort experienced as a conse-
quence of isolation and separation. The amount of urine
excreted by the common marmoset is far less (2 to 10
ml) then that observed with the rhesus monkey (300 to
400 ml), resulting in a large variation in measurements
(data not shown).
In Experiment III, we returned to the 24-hour collec-
tion to compensate for the circadian rhythm in urine
excretion observed for HP/LP excretion. In this
Figure 1 Collagen-induced arthritis induced with bovine collagen type II purified from bovine cartilage of the knee. (a) Clinical signs of
active arthritis, such as soft-tissue swelling and redness of affected joints, were scored twice a week using the semiquantitative scale Integrated
Discomfort Score (see Table 2; red line). Number of affected joints (aj) involved in the arthritis is indicated above the dashed line. The monkeys
were weighed twice a week, body weight serving as a surrogate disease marker. Body weight changes over time are expressed as the
percentage of weight relative to day 0 (blue line). (b) A clear difference in swelling was observed between Mi119 (no swelling) and the
prominent swelling in joints of Mi125. Structural changes could not, however, be visualized in corresponding radiograph of these joints. LH, left
hand; RH, right hand. (c) Histology was performed on collagen-induce arthritis-affected proximal interphalangeal joints. Hyperplasia of the
synovium was observed in joints that were clinically affected (Mi125). Signs of synovitis were also observed, however, in clinically nonaffected
joints (Mi119; lymphocytic infiltrate).
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Figure 2 Development of collagen-induced arthritis is independent of the source of collagen type II. (a) Body weight changes over time
are expressed as the percentage of weight relative to day 0 (blue line), and clinical signs were analyzed twice a week and summarized in an
Integrated Discomfort Score (red line). The number of affected joints (aj) involved in the arthritis is indicated above the dashed line. Group I was
immunized with chicken-origin collagen type II (ch-CII): M03136, M05031*, M05041, M04031*, M04111* and M04121. Group II was immunized
with bovine-origin collagen type II: M03137*, M05032, M05042, M05003, M05026* and M05038*. Animals were boosted on day 35 if they did not
develop clinical arthritis at day 28 (black triangles). The upper two lines of graphs are twin siblings (green accolade). *Sacrificed just after the
onset of clinical disease. (b) ch-CII reproducibly induces collagen-induced arthritis (CIA) with high incidence but variable disease course. PID, post
induction day.
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experiment it was observed that the production of HP
and LP was less affected by the disease (Figure 6). Only
severely diseased animals show a marked change in the
excretion of HP/LP.
Profiles of autoreactive T cells and antibodies
The autoimmune attack on the joints in CIA models in
mice, rats and rhesus monkeys is mediated by interplay
of anti-CII T cells and humoral factors. In both rodent
CIA models [18] as well as the CIA model in the rhesus
monkey [16], a key pathogenic role of IgM autoantibo-
dies was found. Rhesus monkeys that were genetically
resistant to CIA were found incapable of producing ade-
quate amounts of anti-collagen IgM [19]. Second, pre-
sensitization of rhesus monkeys with heat-denatured CII
not only abrogated the capacity to produce anti-CII
IgM, but also induced resistance to CIA [20]. The rela-
tion between both autoimmune parameters and disease
was therefore also tested in the novel CIA model in
marmosets.
Antibodies
In Experiment I, all animals produced CII-specific IgM
and IgG (for animal Mi137 only after boosting on day
114; Figure 7a, b). For Experiment II, the induction pro-
tocol was adapted to an immunization-boost protocol
resulting in reproducible transient production of CII-
specific IgM (Figure 7c, e) followed by a sustained pro-
duction of CII-specific IgG in all 12 animals (Figure
7d, f ). Since this analysis requires substantial amounts
of serum, blood was selected for use in Experiment III
for a longitudinal analysis of cellular responses.
T cells
Two types of analysis have been performed with cells
from the monkeys. A longitudinal analysis of T-cell
immunity development was performed with freshly iso-
lated PBMC (Experiment III) at 28-day interval and a
biodistribution analysis of CII-responsive T cells at
necropsy. Moreover, we performed a fine specificity ana-
lysis of the T-cell response against CII as well as CD4/
CD8 phenotyping of the CII-responsive T cells (Experi-
ment II). Owing to limitations in the available venous
blood volume that can be collected per month during
the course of a study, this assay was performed only at
necropsy when sufficient cells could be obtained.
Figure 8a shows that T-cell responses in peripheral
blood are variable and do not correlate with the course
of the disease. Higher responses can be measured in
spleen and lymph nodes, especially the axillary lymph
nodes (Figure 8b). From the 12 animals that were used
in Experiment II, 10 animals were analyzed for anti-CII
T-cell proliferation. Using dilution of the vital dye car-
boxyfluorescein succinimidyl ester in combination with
monoclonal antibody staining, the phenotype of CII-
responsive cells was determined. In four animals we
could show CII-specific responses especially in axillar
and inguinal lymph nodes (an example is shown in Fig-
ure 8c). Both CD3+/CD4+ T cells and CD3+/CD8+
T cells seem to contribute to the CII-specific response.
In three animals we could not demonstrate a CII-
specific cellular response, and in three animals the data
could not be analyzed due to technical failures.
In an attempt to determine the fine specificity of the
proliferating T cells, proliferation was tested against a
panel of 25-mer overlapping peptides (Table 3) spanning
the CB11 fragment of ch-CII (CIIaa 124 to 402). In none of
the cultures, however, could a positive response be
Figure 3 Variable expression of clinical arthritis at the level of
a single joint. The development of clinical arthritis (mild soft
tissues swelling = clinical score 3) post induction day (PID) at the
levels of single joints (proximal and distal interphalangeal joints and
metacarpal region) is indicated in red. If the swelling was
inconclusive, this is indicated with a dashed red line (see right foot
and index finger, PID 32). Black arrows point to the variable swelling
of the indicated joints. CIA, collagen-induced arthritis.
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detected (Figure 9). The epitope against which the CII-
responsive T cells were directed could therefore not be
determined.
Discussion
We report the development of a new preclinically rele-
vant model of arthritic disease in the common marmo-
set. The marmoset is a small-sized Neotropical primate
that gains increasing popularity as a model of human
diseases. The advantages compared with other fre-
quently used nonhuman primates, such as the rhesus
monkey and cynomolgus macaque, are obvious. Marmo-
sets breed easily in captivity, giving birth to four siblings
per couple per year, which reach adulthood after 1.5
years of age. The small size, 350 to 400 g at adult age,
implies that much lower amounts of test substance can
Figure 4 Histology of affected joints of animals with early-onset arthritis induced with chicken-origin collagen type II. Histology of the
affected joint of a representative animal with early-onset arthritis (M03136) induced with chicken-origin collagen type II. (a) The swollen joint,
subsequently analyzed for histopathology in panels (b) to (e). (b) Overview of the affected joint. (c) Focus on the phenomena observed in (b)
displaying prominent extraarticular infiltrates and highly active bone marrow, (d) resulting in erosion of the bone and disruption of the cartilage.
(e) Manifestation of subcutaneous inflammation and infiltrates at the periosteum.
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Figure 5 Differences in hematological parameters between early-onset arthritis and chronic development. No major differences in
hematological parameters were observed in animals with early onset (red line) of disease and animals with a more chronic development (late =
black line) of arthritis. Hb, hemoglobin; PID, post induction day.
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be used compared with the more than 10-fold larger
macaques. A particularly attractive aspect is that mar-
mosets are born as complete bone marrow chimeras,
which implies a high immunological similarity. This
principle can be used in therapy trials with one twin sib-
ling as the recipient of experimental treatment and the
other sibling the recipient of placebo. Moreover, the
allotolerance between twin siblings allows the transfer of
suspected pathogenic T-cell specificities - a standard
research tool in inbred rodent disease models, but one
that is precluded by the genetic diversity in outbred
macaque models.
For the development of a CIA model in the marmoset
we relied on our experience with rat and rhesus monkey
models of CIA [12,14-16] and with the marmoset as a
model of the chronic progressive immune-mediated
inflammatory disorder multiple sclerosis, EAE
[5,7,10,11]. We chose to examine whether a similarly
valid model for chronic progressive arthritis as for mul-
tiple sclerosis could be developed in the marmoset. The
only difference between EAE and CIA is the immunizing
antigen, being recombinant human myelin/oligodendro-
cyte glycoprotein for the EAE model and type II col-
lagen for the CIA model.
Figure 6 Urine excretion rates of the collagen crosslinks lysylpyrridinoline and hydroxylysylpyrridinoline. Urine samples were collected
twice weekly and the excretion rates of the major collagen-crosslinks (a), (c) hydroxylysylpyrridinoline (HP) and (b), (d) lysylpyrridinoline (LP)
were determined as described in Materials and methods. Urinary excretion rates were normalized to creatinine levels to compensate for a
possible dilution factor. In Experiment I, two animals with overt clinical arthritis (Mi121, Mi125) show increased production from either (a) HP
and/or (b) LP. In Experiment III, the production of (c) HP and (d) LP was less affected by the disease. Only in animals with a high number of
joints involved in the disease ( > 10 affected joints) was an increased production of both HP and LP observed. PID, post induction day.
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Similar to the EAE model, we observed in the CIA
model an almost 100% disease incidence (only one out-
lier in 22 cases) and a heterogeneous clinical course.
This feature probably reflects the genetic heterogeneity
of this outbred species. The variety of disease patterns
included acute cases with a rapid disease onset without
remissions, relapsing/remitting cases with alternating
episodes of inflammation and recovery, and progressive
cases with slowly incrementing disease scores. Especially
in the more chronic cases, inflammation of individual
joints is disseminated in time and space, suggesting
competition between systemically acting proinflamma-
tory mechanisms with locally acting anti-inflammatory
mechanisms. This principle was also observed in the
EAE model and has helped to identify the specificity
and mode of action of the core pathogenic T cells
(reviewed in [11]).
Histological examination of affected joints showed the
same pathological aspects as observed in the rhesus
monkey CIA model - namely, strong synovial
Figure 7 Humoral responses play a prominent role in development of collagen-induced arthritis in the common marmoset. In
Experiment I where a semi-purified collagen type II (CII) was used, (a) a transient CII-specific IgM response was followed by (b) a sustained CII-
specific IgG response. Even in animal Mi137 this phenomenon was observed after the booster at day 110. In Experiment II where commercial
batches of CII were used both against (c), (d) bovine CII and (e), (f) chicken CII, a transient CII-specific IgM response ((c) and (e)) was followed
by a sustained CII-specific IgG response ((d) and (f)). PID, post induction day.
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hyperplasia forming pannus tissue overgrowing and
eroding the cartilage surface and degradation of
subchondral bone [3,4]. Besides the clear articular
pathology, extraarticular pathology could also be
observed - such as inflammation of the subcutaneous
tissue, inflammation of the periosteum, development of
perivasculitis, presence of reactive blood vessels and
angiogenesis. Together, the features discussed thus far
mark a considerable improvement compared with the
acute self-remitting CIA model in rhesus monkeys.
For the immune profiling we have focused on para-
meters that were found of pathogenic relevance in the
rhesus monkey CIA model - namely, the capacity to
generate IgM and IgG autoantibodies [14,20] and the
presence of a T-cell proliferative response [19]. One of
the few disadvantages of the marmoset model is the low
amount of blood that can be collected for analysis of
cellular immune reactions, which is about 3 ml per
month. T-cell proliferation in PBMC was therefore only
assessed once every 28 days. The results show a variable
proliferative response, which displayed no obvious rela-
tion with the clinical course. The analysis at necropsy
showed that the vast majority of CII-responsive T cells
is located in the lymphoid organs, spleen and axillary
lymph nodes in particular, which most probably explains
this poor discrepancy. Only at necropsy could sufficient
cells be obtained from blood and lymphoid organs for
phenotyping of the CII-responsive cells and a fine speci-
ficity analysis of the anti-CII T-cell response. Interest-
ingly, in the axillary lymph nodes that are located in the
armpits, we observed not only the expected specific pro-
liferation of CD4+ T cells, but also proliferation of CD8+
T cells. Although in several monkeys good proliferative
responses were detected against the complete CII
Figure 8 T-cell proliferation responses. (a) From the six animals in Experiment III, a longitudinal analysis of collagen type II (CII)-specific T-cell
responses in freshly isolated peripheral blood mononuclear cells (PBMC) shows a variable response against denatured CII (animal identification at
top of the graph). #Day of necropsy. (b) At the day of necropsy, CII-specific proliferative responses were measured from the six animals in
Experiment III. Cells isolated from the lymph nodes (spleen, axillar and inguinal) show better responses than cell isolated from the PBMC. (c)
From 10 animals in Experiment II, the CII-specific responses were analyzed using dilution of the vital dye carboxyfluorescein succinimidyl ester in
combination with cellular staining for the T-cell markers CD3, CD4 and CD8. It was shown for four out of the 10 animals analyzed that, especially
in axillar and inguinal lymph nodes (LN), both CD3+/CD4+ T cells and CD3+/CD8+ T cells contribute to the CII-specific cellular responses (a
representative experiment of those four animals is presented; animal M04111). Stimulation index = proliferation of experimental sample (counts
per minute)/proliferation of medium control (counts per minute). ch-CII, chicken-origin collagen type II; PID, post induction day.
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Figure 9 Fine specificity of proliferating T cells. A detailed analysis of collagen type II (CII)-specific T-cell responses against a cyanogen
bromide fragment 11 (CB11)-derived overlapping peptide set (see Table 3) was performed on the day of necropsy with freshly isolated
peripheral blood mononuclear cells (PBMC) (green) and cells isolated from the inguinal (red) and axillar (blue) lymph nodes and the spleen
(yellow) (animal identification given in the graph). Concanavin (Con) A stimulation was included to establish functional proliferation of the
different cell populations and displayed stimulation indices ranging from 25 to 160. In general, CII-specific proliferative responses are better
measured in lymph nodes (spleen, axillar and inguinal) than in PBMC. Stimulation index = proliferation of experimental sample (counts per
minute)/proliferation of medium control (counts per minute).
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protein, none of the synthetic 25-mer peptides derived
from the immunogenic CB11 fragment of ch-CII could
stimulate proliferation.
Conclusions
The common marmoset may fill a niche as an attractive
alternative nonhuman primate species for preclinical
evaluation of new biologicals in the field of arthritis.
The small size of the common marmoset compared
with the rhesus monkey translates into lower caging,
feeding and housing costs. This advantage coupled with
the lower purchase price of common marmosets com-
pared with macaques may translate into substantial cost
savings when performing equivalent studies in rhesus
monkeys. Furthermore, the marmoset is easier to handle
than the aggressive rhesus monkeys, which need to be
sedated for every handling [21,22]. Of note is the fact
that the evolutionary distance between the common
marmoset and human is 33 million years while the evo-
lutionary distance between the rhesus monkey and
human is 23 million years [23]. This translates into sig-
nificant homology differences between human and the
common marmoset, which is demonstrated by the fact
that a substantial number of ELISAs that crossreact
with rhesus cytokines do not crossreact with cytokines
from the common marmoset (personal observation).
Evaluation of a promising new compound for RA in the
common marmoset will always require establishing
crossreactivity of this new compound for targets in the
common marmoset. For this purpose we have stored tis-
sue in Oxidized Regenerated Cellulose at -80°C, allowing
for immunohistochemistry and isolated mononuclear
cells from axillar and inguinal lymph nodes, spleen and
blood in liquid nitrogen for functional assays.
The common marmoset already plays an important
role in diverse areas of research such as infectious dis-
eases [24,25], stem cell research, neural and cognitive
sciences [5,10,26], reproductive biology, toxicology and
drug development [27,28]. We believe in the years to
come that the CIA model in the common marmoset
may fill a void for drug development in the area of
immune-mediated inflammatory diseases.
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